AndreaBozzo/ceres-open-data-index huggingface dataset:
Quality Improvement Center for Adoption and Guardianship Support and Preservation (QIC-AG)

The Children’s Bureau, Administration for Children and Families, Department of Health and Human Service established the National Quality Improvement Center for Adoption and Guardianship Support and Preservation (QIC-AG). In October 2014, the QIC-AG was awarded to Spaulding for Children in partnership with The University of Texas at Austin, The University of Wisconsin at Milwaukee, and The University of North Carolina at Chapel Hill. The QIC-AG was designed to promote permanence, when reunification is no longer a goal, and improve adoption and guardianship preservation and support.

For five years, the QIC-AG team worked with eight sites across the nation, with the purpose to implement evidence-based interventions or develop and test promising practices which, if proven effective, could be replicated or adapted in other child welfare jurisdictions. However, for the NDACAN archive, data from only 6 of the sites are included. These sites are from the following jurisdictions: Catawba County (NC), Illinois, New Jersey, Tennessee, Vermont and Wisconsin.

The six sites included in the NDACAN dataset all served the following broad target population, defined by the funder as: “Children and youth and their adoptive or guardianship families who have already finalized the adoption or guardianship and for whom stabilization may be threatened will also be targeted for support and service interventions. The children and youth in this target group may have been adopted through the child welfare system or by private domestic or intercountry private agency involvement.”

The primary research question was: Do families with a finalized adoption or guardianship have increased post-permanency stability and improved well-being if they receive post permanency services and support compared with similar families who receive services as usual? The project’s short-term outcomes varied by site and included, for example, increased level of caregiver commitment; reduced levels of family stress; improved familial relationships; and reduced child behavioral issues. The project had three long-term outcomes: increased post-permanency stability, improved behavioral health for children, and improved child and family well-being.

Investigators: Nancy Rolock, PhD
Case Western Reserve University, Cleveland, OHRowena Fong, EdD
The University of Texas at Austin,  Austin, TX
Service Area PUF - PY2018

The Service Area PUF (SA-PUF) is one of the files that make up the Marketplace PUF. The SA-PUF contains issuer-level data on the geographic coverage or service area (i.e., where the plan is offered) including state, county, and zip code. These data either originate from the Service Area template (i.e., template field), an Excel based form used by issuers to describe their plans in the QHP/SADP application process, or were generated by CCIIO for use in data processing (i.e., system-generated).
Morphine sulfate

Morphine Sulfate is a prescription opioid medication used to manage severe pain. It comes as an oral solution with a strength of 20 mg/mL, available in bottles of various sizes (15 mL, 30 mL, 120 mL, 240 mL). Manufactured by SpecGx LLC, it's a Schedule II controlled substance due to its potential for abuse. This information was generated using AI and is provided for informational and research purposes only.
Compound 525823: N,N-Dimethyl-N'-(3-bromophenyl)-propionamidine

Chemical compound data from PubChem database. IUPAC Name: N'-(3-bromophenyl)-N,N-dimethylpropanimidamide. Molecular Formula: C11H15BrN2. Molecular Weight: 255.15. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Lung surfactant in subacute pulmonary disease

Pulmonary surfactant is a surface active material composed of both lipids and proteins that is produced by alveolar type II pneumocytes. Abnormalities of surfactant in the immature lung or in the acutely inflamed mature lung are well described. However, in a variety of subacute diseases of the mature lung, abnormalities of lung surfactant may also be of importance. These diseases include chronic obstructive pulmonary disease, asthma, cystic fibrosis, interstitial lung disease, pneumonia, and alveolar proteinosis. Understanding of the mechanisms that disturb the lung surfactant system may lead to novel rational therapies for these diseases.
The PRC-barrel: a widespread, conserved domain shared by photosynthetic reaction center subunits and proteins of RNA metabolism

The PRC-H β-barrel domain, a distinct cytoplasmic β-barrel domain whose fold has no close structural relationship to any other well known β-barrel domain, is the prototype of a novel superfamily of protein domains approximately 80 residues long. This domian is a widespread, ancient domain that appears to have been recruited to a variety of biological systems, ranging from RNA processing to photosynthesis.
Compound 525813: N-Phenyl-N'-3-bromophenylformamidine

Chemical compound data from PubChem database. IUPAC Name: N-(3-bromophenyl)-N'-phenylmethanimidamide. Molecular Formula: C13H11BrN2. Molecular Weight: 275.14. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 526179: 3-Methyl-4-oxo-1,2-dithiane

Chemical compound data from PubChem database. IUPAC Name: 3-methyldithian-4-one. Molecular Formula: C5H8OS2. Molecular Weight: 148.3. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
NNDSS - Table II. Invasive Pneumococcal Diseases, All Ages

NNDSS - Table II. Invasive Pneumococcal Diseases, All Ages - 2017. In this Table, provisional cases of selected notifiable diseases (≥1,000 cases reported during the preceding year), and selected low frequency diseases are displayed. The Table includes total number of cases reported in the United States, by region and by states, in accordance with the current method of displaying MMWR data.  Data on United States exclude counts from US territories.

Note:
These are provisional cases of selected national notifiable diseases, from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published weekly as numbered tables printed in the back of the Morbidity and Mortality Weekly Report (MMWR). Cases reported by state health departments to CDC for weekly publication are provisional because of ongoing revision of information and delayed reporting. 

Case counts in this table are presented as they were published in the MMWR issues. Therefore, numbers listed in later MMWR weeks may reflect changes made to these counts as additional information becomes available. 

Footnotes:
 C.N.M.I.: Commonwealth of Northern Mariana Islands. 

 U: Unavailable. —: No reported cases. N: Not reportable. NN: Not Nationally Notifiable. NP: Nationally notifiable but not published. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum. 

*Three low incidence conditions, rubella, rubella congenital, and tetanus, are in Table II to facilitate case count verification with reporting jurisdictions. 

† Case counts for reporting year 2017 are provisional and subject to change. For further information on interpretation of these data, see http://wwwn.cdc.gov/nndss/document/ ProvisionalNationaNotifiableDiseasesSurveillanceData20100927.pdf. Data for tuberculosis are displayed in Table IV, which appears quarterly.

§ Includes drug resistant and susceptible cases of Invasive Pneumococcal Disease. This condition was previously named Streptococcus pneumoniae invasive disease and cases were reported to CDC using different event codes to specify whether the cases were drug resistant or in a defined age group, such as <5 years.
Conservation of long-range synteny and microsynteny between the genomes of two distantly related nematodes

To assess whether the pattern of high rates of genome rearrangement, with a bias towards within-chromosome events is true of nematodes in general, genome sequence was used to compare the model Caenorhabditis elegans and the filarial parasite Brugia malayi. It is suggested that intrachromosomal rearrangement is a major force driving chromosomal organization in nematodes.
Compound 529118: 4-Quinazolone, 3-ethyl-2-methyl

Chemical compound data from PubChem database. IUPAC Name: 3-ethyl-2-methylquinazolin-4-one. Molecular Formula: C11H12N2O. Molecular Weight: 188.23. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Monoclonal antibodies against the iron regulated outer membrane Proteins of

Background
          Iron is an important nutrient required by all forms of life.In the case of human hosts,the free iron availability is 10-18M,which is far less than what is needed for the survival of the invading bacterial pathogen.To survive in such conditions, bacteria express new proteins in their outer membrane and also secrete iron chelators called siderophores.
        
        
          Results/ Discussion
          Acinetobacter baumannii ATCC 19606, a nosocomial pathogen which grows under iron restricted conditions, expresses four new outer membrane proteins,with molecular weight ranging from 77 kDa to 88 kDa, that are called Iron Regulated Outer Membrane Proteins (IROMPs). We studied the functional and immunological properties of IROMPs expressed by A.baumanii ATCC 19606.The bands corresponding to IROMPs were eluted from SDS-PAGE and were used to immunize BALB/c mice for the production of monoclonal antibodies. Hybridomas secreting specific antibodies against these IROMPs were selected after screening by ELISA and their reactivity was confirmed by Western Blot. The antibodies then generated belonged to IgM isotype and showed bactericidical and opsonising activities against A.baumanii in vitro.These antibodies also blocked siderophore mediated iron uptake via IROMPs in bacteria.
        
        
          Conclusion
          This proves that iron uptake via IROMPs,which is mediated through siderophores,may have an important role in the survival of A.baumanii inside the host,and helps establishing the infection.
Mycophenolate mofetil

Mycophenolate mofetil is a generic prescription drug available as 250 mg oral capsules. It acts as an antimetabolite immunosuppressant, often used to prevent organ rejection in transplant patients. Manufactured by AvKARE under ANDA090055, it comes in bottles of 100 or 500 capsules, with marketing starting May 25, 2025. This information was generated using AI and is provided for informational and research purposes only.
Patent AT-E400165-T1: [Translated] CARRIER ARM, IN PARTICULAR FOR CARRYING AN IMPLEMENTATION HEAD FOR AN IMPLEMENTATION MACHINE, AND IMPLEMENTATION MACHINE FOR IMPLEMENTING SUBSTRATES WITH ELECTRICAL COMPONENTS

The arm has a base body having carbon fiber reinforced plastic and an extension unit (12) having a mounting surface (16) with which the extension unit is attached to the arm in a mounting area. A support unit is made of glass-fiber reinforced plastic and is connected with the body in such a manner that the mounting surface partially lies under two sections that are made of carbon and glass fiber reinforced plastics.
Bismuth subcitrate potassium, metronidazole, tetracycline hydrochloride

This prescription medication combines bismuth subcitrate potassium (140 mg), metronidazole (125 mg), and tetracycline hydrochloride (125 mg) in oral capsules. It's used to treat infections caused by Helicobacter pylori bacteria, often in combination with other therapies for stomach ulcers or gastritis. Take as directed by a doctor. This information was generated using AI and is provided for informational and research purposes only.
Peginterferon alfa-2a

PEGASYS (peginterferon alfa-2a) is a prescription medication manufactured by pharmaand GmbH, classified as an interferon alpha. It's administered via subcutaneous injection and comes in syringe or vial forms with strengths like 180 mcg per dose. This drug is used to treat conditions such as chronic hepatitis C. This information was generated using AI and is provided for informational and research purposes only.
Delaware 2016 Potential Areas for Addressing Service Gaps for Opioid Treatment

The purpose of the medication-assisted treatment (MAT) facility maps is to identify areas on a state-by-state basis that may be potentially underserved by existing treatment facilities. The maps are created with a methodology that seeks to include the highest potential need areas from individual counties so that county-level stakeholders are also informed. The maps are meant to be used as a tool for policy makers to determine potentially underserved areas—not as a definitive representation of these areas.
Compound 529877: Pyrazine, 2-(2-thienylmethyl)-3,6-dimethyl

Chemical compound data from PubChem database. IUPAC Name: 2,5-dimethyl-3-(thiophen-2-ylmethyl)pyrazine. Molecular Formula: C11H12N2S. Molecular Weight: 204.29. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Dexamethasone

Dexamethasone is a prescription corticosteroid medication available as oral tablets in strengths of 0.5 mg, 0.75 mg, 1 mg, 1.5 mg, 2 mg, 4 mg, and 6 mg. Manufactured by Apotex Corp., it works by acting as a hormone receptor agonist to reduce inflammation and suppress the immune system. It's used for various conditions like allergies, arthritis, and certain cancers. This information was generated using AI and is provided for informational and research purposes only.
Compound 529312: Oxetane, 3-ethyl-3-butyl

Chemical compound data from PubChem database. IUPAC Name: 3-butyl-3-ethyloxetane. Molecular Formula: C9H18O. Molecular Weight: 142.24. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E401534-T1: [Translated] METHOD AND DEVICE FOR FEEDING INDUSTRIAL FIREPLACES WITH WASTE MATERIAL, IN PARTICULAR SECONDARY FUELS

The invention relates to a method and device for feeding industrial combustion plants with wastes, in particular with secondary fuels, and to the thus produced fuel, in order to better use, in particular a secondary fuel and to obtain a low-cost usable product which can be introduced into a combustion chamber in an improved manner, especially in order to reliably avoid obstructions in ducts leading to a boiler. The inventive method consists in crushing wastes in a crushing unit, extracting crushed wastes from said crushing unit practically just prior to the introduction thereof into the boiler by means of a conveyer which is arranged in an extracting device, on a pneumatic conveyer and in transporting said wastes to the combustion chamber by means of the pneumatic conveyer.
Compound 529899: 3-(4-Hydroxy-3-methoxyphenyl)propionaldehyde

Chemical compound data from PubChem database. IUPAC Name: 3-(4-hydroxy-3-methoxyphenyl)propanal. Molecular Formula: C10H12O3. Molecular Weight: 180.2. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 526364: 4-Bromo-1,2,6,7,9-pentachloro-dibenzo-p-dioxin

Chemical compound data from PubChem database. IUPAC Name: 4-bromo-1,2,6,7,9-pentachlorodibenzo-p-dioxin. Molecular Formula: C12H2BrCl5O2. Molecular Weight: 435.3. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 527712: 2,4-Dichlorodibenzofuran

Chemical compound data from PubChem database. IUPAC Name: 2,4-dichlorodibenzofuran. Molecular Formula: C12H6Cl2O. Molecular Weight: 237.08. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 527612: Allyl tribromoacetate

Chemical compound data from PubChem database. IUPAC Name: prop-2-enyl 2,2,2-tribromoacetate. Molecular Formula: C5H5Br3O2. Molecular Weight: 336.8. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
The CONSORT statement: revised recommendations for improving the quality of reports of parallel group randomized trials

To comprehend the results of a randomized controlled trial (RCT), readers must understand its design, conduct, analysis and interpretation. That goal can only be achieved through complete transparency from authors. Despite several decades of educational efforts, the reporting of RCTs needs improvement. Investigators and editors developed the original CONSORT (Consolidated Standards of Reporting Trials) statement to help authors improve reporting by using a checklist and flow diagram. The revised CONSORT statement presented in this paper incorporates new evidence and addresses some criticisms of the original statement.
        The checklist items pertain to the content of the Title, Abstract, Introduction, Methods, Results and Discussion. The revised checklist includes 22-items selected because empirical evidence indicates that not reporting the information is associated with biasedestimates of treatment effect or the information is essential to judge the reliability or relevance of the findings. We intended the flow diagram to depict the passage of participants through an RCT. The revised flow diagram depicts information from four stages of a trial (enrolment, intervention allocation, follow-up, and analysis). The diagram explicitly includes the number of participants, for each intervention group, included in the primary data analysis. Inclusion of these numbers allows the reader to judge whether the authors have performed an intention-to-treat analysis.
        In sum, the CONSORT statement is intended to improve the reporting of an RCT, enabling readers to understand a trial's conduct and to assess the validity of its results.
Compound 528332: Dehydronepetalactone

Chemical compound data from PubChem database. IUPAC Name: 4,7-dimethyl-6,7-dihydro-5H-cyclopenta[c]pyran-1-one. Molecular Formula: C10H12O2. Molecular Weight: 164.2. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Racial/Ethnic Differences in Mental Health Service Use Among Adults and Adolescents (2015-2019)

This chartbook uses combined 2015 to 2019 data from the National Survey on Drug Use and Health (NSDUH) to present nationally representative estimates of mental health service utilization among adults aged 18 or older and adolescents aged 12 to 17 within different racial/ethnic groups in the United States. The percentages are annual averages.
Dexmethylphenidate hydrochloride

Dexmethylphenidate Hydrochloride is a generic prescription medication, available as oral tablets in 2.5 mg, 5 mg, and 10 mg strengths. It's a central nervous system stimulant classified as a Schedule II controlled substance, used to treat attention deficit hyperactivity disorder (ADHD). Manufactured by Ascend Laboratories, LLC, under ANDA212631. This information was generated using AI and is provided for informational and research purposes only.
Patent AT-E401800-T1: [Translated] HIGHLY INTENSIVE SWEETENER COMPOSITION AND DELIVERY THEREOF

Chemical patent from PubChem database. Patent Number: AT-E401800-T1. Title: Improved Chemical Process. Filing Date: 1993-05-06. Inventors: Kim, Young-Soo, Taylor, Elizabeth. Abstract: An improved chemical process is disclosed, featuring enhanced yield, reduced reaction time, and improved environmental profile compared to conventiona... IPC Classifications: C07H, A61K, A61P. This patent covers 47 claims related to 9 chemical compounds. Useful for intellectual property research, prior art searches, and chemical innovation tracking.
Cluster-Rasch models for microarray gene expression data

Background
          We propose two different formulations of the Rasch statistical models to the problem of relating gene expression profiles to the phenotypes. One formulation allows us to investigate whether a cluster of genes with similar expression profiles is related to the observed phenotypes; this model can also be used for future prediction. The other formulation provides an alternative way of identifying genes that are over- or underexpressed from their expression levels in tissue or cell samples of a given tissue or cell type.
        
        
          Results
          We illustrate the methods on available datasets of a classification of acute leukemias and of 60 cancer cell lines. For tumor classification, the results are comparable to those previously obtained. For the cancer cell lines dataset, we found four clusters of genes that are related to drug response for many of the 90 drugs that we considered. In addition, for each type of cell line, we identified genes that are over- or underexpressed relative to other genes.
        
        
          Conclusions
          The cluster-Rasch model provides a probabilistic model for describing gene expression patterns across samples and can be used to relate gene expression profiles to phenotypes.
Hepatic adverse events during highly active antiretroviral therapy containing nevirapine: a case report

Background
          Hepatotoxicity is one of the most serious complications of highly active antiretroviral therapy (HAART). The aim of this report is to analyse an HIV infected patient on HAART including nevirapine and taking antidepressive agents, with acute toxic hepatitis.
        
        
          Case presentation
          A 39 year old patient diagnosed as HIV positive one month ago administered to the clinical ward of the Department of Infectious Diseases and Clinical Microbiology in Ege University Medical School with high fever, malaise, nausea, diarrheae and elevated liver enzymes (ALT 1558 U/L, AST 4288 U/L). He has been using HAART including zidovudine+lamivudine (2 × 1/day) and nevirapine (2 × 200 mg/day, following dose escalation) for 22 days, sertralin and diazepam for 12 days and lithium for 10 days.
          The patient was hospitalized. Antiretroviral and antidepressant treatments were stopped. The day after admission, his fever dropped and his symptoms improved. Clinical improvement continued on the following days. The patient was discharged upon his request on the 14th day of hospitalization. The liver function tests returned to normal levels in two weeks following discharge.
        
        
          Conclusion
          Close monitoring of liver enzymes during the first 12 weeks of nevirapine therapy is critical to prevent life threatening events.
Compound 529066: 1-[(5-Methyl-2-furanyl)methyl]pyrrolidine

Chemical compound data from PubChem database. IUPAC Name: 1-[(5-methylfuran-2-yl)methyl]pyrrolidine. Molecular Formula: C10H15NO. Molecular Weight: 165.23. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.